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Abstract
Background: As a result of widespread chloroquine and sulphadoxine-pyrimethamine resistance, artemisinin-based
combination therapy (ACT) (which includes artemether-lumefantrine and artesunate-amodiaquine) has been
recommended as a first-line anti-malarial regimen in Senegal since 2006. Since then, there have been very few
reports on the ex vivo susceptibility of Plasmodium falciparum to anti-malarial drugs. To examine whether parasite
susceptibility has been affected by the widespread use of ACT, the ex vivo susceptibility of local isolates was
assessed at the military hospital of Dakar.
Methods: The ex vivo susceptibility of 93 P. falciparum isolates from Dakar was successfully determined using the
Plasmodium lactate dehydrogenase (pLDH) ELISA for the following drugs: chloroquine (CQ), quinine (QN),
mefloquine (MQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA) and
doxycycline (DOX).
Results: After transformation of the isolate IC50 in ratio of IC50 according to the susceptibility of the 3D7 reference
strain (isolate IC50/3D7 IC50), the prevalence of the in vitro resistant isolates with reduced susceptibility was 50% for
MQ, 22% for CQ, 12% for DOX, 6% for both QN and MDAQ and 1% for the drugs LMF and DHA. The highest
significant positive correlations were shown between responses to CQ and MDAQ (r = 0.569; P < 0.0001), LMF and
QN (r = 0.511; P < 0.0001), LMF and DHA (r = 0.428; P = 0.0001), LMF and MQ (r = 0.413; P = 0.0002), QN and DHA
(r = 0.402; P = 0.0003) and QN and MQ (r = 0.421; P = 0.0001).
Conclusions: The introduction of ACT in 2002 has not induced a decrease in P. falciparum susceptibility to the
drugs DHA, MDAQ and LMF, which are common ACT components. However, the prevalence of P. falciparum
isolates with reduced susceptibility has increased for both MQ and DOX. Taken together, these data suggest that
intensive surveillance of the P. falciparum in vitro susceptibility to anti-malarial drugs in Senegal is required.
Background
During the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. The emergence and spread
of drug-resistant parasites has generated an urgent need
for the development of novel anti-malarial drugs. One
strategy for reducing malaria prevalence is the use of
drugs in combination. Drug combinations protect each
component drug from the development of resistance
and reduce the overall transmission of malaria [2]. Since
2001, more than 60 countries have officially adopted
artemisinin-based combination therapy (ACT) for the
treatment of falciparum malaria; moreover, ACT is now
the official first-line treatment against malaria in Africa
[3]. In ACT, the artemisinin derivative causes rapid and
effective reduction of parasite biomass and gametocyte
carriage, while the partner drug, which has an extended
duration of activity, achieves effective clinical and parasi-
tological cure. However, the clinical failures, or at least
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the extended parasite clearance times associated with
ACT have been described in Cambodia [4-7]. In addi-
tion, prior therapy with ACT containing amodiaquine
has selected for P. falciparum isolates with reduced
response to monodesethylamodiaquine, thereby suggest-
ing that amodiaquine-containing regimens may have
rapidly reduced efficacy in Africa [8].
Dakar, the capital city of Senegal, has an urban popu-
lation of approximately 1.1 million and a suburban
population of 2.3 million; the city covers the majority of
the Cap-Vert Peninsular. Malaria is transmitted in
Dakar and its surrounding suburbs, with a human biting
rate ranging from 0.1 to 43.7 bites per person per night,
according to different districts and entomological inocu-
lation rates (EIR) ranging from 0 to 16.8 infected bites
per person per year [9,10]. Malaria transmission rates
are associated with environmental factors, such as vege-
tation and built-up area [11]. Malaria accounted for
25.9% of the total cases observed in the Infectious Dis-
ease Clinic in Dakar between 2001 and 2003. Of those
cases, 65.6% presented as severe forms [12]. In 2004,
malaria attacks accounted for 13.7% (2977 cases) of all
consultations at the Dispensaire St Martin in Dakar,
which increased from October to December [13].
Since 2002, ACT has been routinely and widely used
in Senegal for managing uncomplicated malaria. ACT is
delivered free-of-charge in health centres. Together,
artemether-lumefantrine and artesunate-amodiaquine
were the ACT recommended as the first-line anti-malar-
ial regimen since it became available in the public sys-
tem in 2006. Since then, more than 1.5 million
treatments have been administered [14]. In 2002-2003,
an open randomized study with the drug Artequin®
(artesunate-mefloquine) showed an excellent clinical and
parasitological response rate of 100% on day 28 [15]. In
2008, in Kaolack (200 km south-east of Dakar), a study
showed that Artequin was efficacious in paediatric
patients with a cure rate of 96.2% in intention-to-treat
analysis and was as well tolerated as artemether-lume-
fantrine [16]. Artesunate-amodiaquine associated cure
rates were > 99.3% in Mlomp and Keur-Socé when
administered either as a single daily intake or two daily
intakes [17]. The fixed-dose combination of artesunate-
amodiaquine (ASAQ) shows a cure rate > 98.5% [18].
The cure rates were 100% in both populations experien-
cing a second and third episode of uncomplicated
malaria following treatment with ASAQ [14].
Since the introduction of ACT in Senegal, there have
been very few reports on the ex vivo susceptibility of P.
falciparum to anti-malarial drugs. To examine whether
parasite susceptibility has been affected by the wide-
spread use of ACT, an ex vivo susceptibility study was
conducted with local isolates obtained at the military
hospital of Dakar. The new term ‘ex vivo susceptibility’
is used to describe studies on fresh isolates, while the
term ‘in vitro susceptibility’ should now refer to studies
on strains of the parasite, which have been either kept
in culture for at least two to three generations or which
have been cryo-preserved. The malaria isolates obtained
from patients at the Hôpital Principal de Dakar were
assessed for susceptibility to chloroquine (CQ), quinine
(QN), monodesethylamodiaquine (MDAQ), the active
metabolite of amodiaquine, mefloquine (MQ), lumefan-
trine (LMF), dihydroartemisinin (DHA), the active meta-
bolite of artemisinin derivatives and doxycycline (DOX).
Methods
Plasmodium falciparum isolates
In total, 188 patients with malaria were recruited from
14 October 2009 to 19 January 2010 at the Hôpital Prin-
cipal de Dakar. Venous blood samples were collected in
Vacutainer® ACD tubes (Becton Dickinson, Rutherford,
NJ, USA) prior to patient treatment; blood samples were
used to test drug susceptibility within less than 12 hours
(h) of collection. Informed verbal consent was obtained
from patients and/or their parents before blood collec-
tion. Susceptibility tests were performed on the same
blood samples used for malaria diagnosis. The study was
reviewed and approved by the ethical committee of
Hôpital Principal de Dakar.
Thin blood smears were stained using a RAL® kit
(Réactifs RAL, Paris, France) and were examined to
determine P. falciparum density and to confirm mono-
infection. Parasitized erythrocytes were washed three
times in RPMI 1640 medium (Invitrogen, Paisley, UK)
buffered with 25 mM HEPES and 25 mM NaHCO3. If
parasitaemia exceeded 0.8%, infected erythrocytes were
diluted to 0.4% with uninfected erythrocytes (human
blood type A+) and re-suspended in RPMI 1640 med-
ium supplemented with 10% human serum (Abcys S.A.
Paris, France), for a final haematocrit of 1.5%.
Drugs
CQ, QN, DHA and DOX were purchased from Sigma
(Saint Louis, MO, USA). MDAQ was obtained from the
World Health Organization (Geneva, Switzerland), MQ
was purchased from Roche (Paris, France) and LMF was
purchased from Novartis Pharma (Basel, Switzerland).
QN, MDAQ, MQ, DHA and DOX were dissolved first
in methanol and then diluted in water to final concen-
trations ranging from 5 nM to 3200 nM for QN, 1.56
nM to 1000 nM for MDAQ, 3.2 nM to 400 nM for
MQ, 0.1 nM to 100 nM for DHA and 0.1 μM to 502
μM for DOX. CQ was re-suspended and diluted in
water to final concentrations ranging from 5 nM to
3200 nM. LMF was re-suspended and diluted in ethanol
to obtain final concentrations ranging from 0.5 nM to
310 nM.
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The batches of plates were tested and validated on the
CQ-susceptible 3D7 strain (West-Africa) and the CQ-
resistant W2 strain (Indochina) (MR4, Virginia, USA) in
3 to 6 independent experiments using both the standard
42-h 3H-hypoxanthine uptake inhibition method [19] in
controlled atmospheric conditions in an incubator (5%
CO2, 10% O2 and 85% N2) and the Plasmodium lactate
dehydrogenase (pLDH) ELISA [20,21] with the same
conditions described in the paragraph below. The two
strains were synchronized twice with sorbitol before use
[22], and clonality was verified every 15 days using PCR
genotyping of the polymorphic genetic markers msp1
and msp2 and using microsatellite loci [23,24] and each
year by an independent laboratory from the Worldwide
Anti-malarial Resistance Network (WWARN).
Ex vivo assay
For the in vitro isotopic microtests, 200 μl of synchro-
nous parasitized red blood cells (final parasitaemia,
0.5%; final haematocrit, 1.5%) was aliquoted into 96-well
plates pre-dosed with anti-malarial drugs. The plates
were incubated in a sealed bag for 42 h at 37°C with the
atmospheric generators for capnophilic bacteria Genbag
CO2® at 5% CO2 and 15% O2 (BioMérieux; Marcy
l’Etoile, France) [25]. After thawing the plates, haemo-
lysed cultures were homogenized by vortexing the
plates. Both the success of the drug susceptibility assay
and the appropriate volume of haemolysed culture to
use for each assay were determined for each clinical iso-
late during a preliminary pLDH ELISA. This pre-test
and the subsequent ELISAs were performed using the
commercial kit (ELISA-Malaria antigen test, ref 750101,
DiaMed AG, Cressier s/Morat, Switzerland) as pre-
viously described [20]. The optical density (OD) of each
sample was measured with a spectrophotometer (Multis-
kan EX, Thermo Scientific, Vantaa, Finland).
The concentration at which the drugs were able to
inhibit 50% of parasite growth (IC50) was calculated
with the inhibitory sigmoid Emax model with estimation
of the IC50 through non-linear regression using a stan-
dard function of the R software (ICEstimator version
1.2) [26]. IC50 values were validated only if the OD ratio
(OD at concentration 0/OD at concentration max) was
superior to 1.8 and the confidence interval ratio (upper
95% confidence interval of the IC50 estimation/lower
95% confidence interval of the IC50 estimation) was
inferior to 2.0 [26].
Statistical analysis
IC50 values were analysed after logarithmic transforma-
tion and expressed as the geometric mean of the IC50
and the confidence interval 95% (CI95%). Assessment of
cross-resistance between the seven anti-malarial drugs
was measured by pair-wise correlation of IC50 values of
all isolates and estimated by the Pearson coefficient of
correlation (r) and the coefficient of determination (r2).
The cut-off values for in vitro resistance, or reduced
susceptibility, were re-evaluated under experimental
conditions induced by the use of the atmospheric gen-
erators for capnophilic bacteria Genbag CO2 by regres-
sion. This experiment was performed to compare the
prevalence of isolates with in vitro resistance, or reduced
susceptibility, tested in Genbag conditions [25] with the
prevalence of isolates using the standard 42-h 3H-
hypoxanthine uptake inhibition method in controlled
atmospheric conditions in the incubator (5% CO2, 10%
O2 and 85% N2) [19] with a cut-off concentration of
100 nM, 80 nM, 150 nM, 10.5 nM, 800 nM, 30 nM and
35 μM for CQ, MDAQ, LMF, DHA, QN, MQ and
DOX, respectively. Using the Plasmodium lactate dehy-
drogenase (pLDH) ELISA in Genbag conditions, the
values were 77 nM, 61 nM, 115 nM, 12 nM, 611 nM,
30 nM and 37 μM for CQ, MDAQ, LMF, DHA, QN,
MQ and DOX, respectively. An IC50 ratio (IC50 of clini-
cal isolate/mean IC50 of 3D7 on the same batch of
plates tested in 3 to 6 independent experiments) was
calculated for each anti-malarial drug and each isolate
in accordance with the guidelines of the WWARN.
These ratios were also analysed after logarithmic trans-
formation and expressed as the geometric mean of the
ratios and the confidence interval 95% (CI95%). 3D7
ratio cut-offs were estimated for in vitro resistance or
reduced susceptibility by calculating the ratio of stan-
dard threshold at Genbag CO2® conditions/3D7 IC50
mean. These values were 5 (CQ), 3 (MDAQ), 5 (LMF),
7 (DHA), 5 (QN), 0.6 (MQ) and 3 (DOX).
Consent
The study was reviewed and approved by the ethics
commission of Hôpital Principal de Dakar.
Results
One hundred and eighty eight patients were recruited
for the study at the Hôpital Principal de Dakar; 147 iso-
lates from these patients were tested ex vivo, and 93 iso-
lates were successfully cultured. After validating the IC50
[(OD at concentration = 0/OD at concentration max) >
1.8 and (upper 95% confidence interval/lower 95% confi-
dence interval) < 2.0], the following proportion of vali-
dated IC50 values were 83 for CQ, 83 for MDAQ, 70 for
LMF, 88 for DHA, 82 for QN, 88 for MQ and 76 for
DOX.
The average parameter estimates for the seven anti-
malarial drugs utilized against the P. falciparum isolates
are given in Table 1. The prevalence of P. falciparum
isolates with in vitro decreased susceptibility to MQ
reached 55% (Table 2). Only 22% of the isolates were
resistant to CQ. The percent of resistant isolates, or
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those with decreased susceptibility, were similar using
the 3D7 ratio cut-offs.
The highest significant positive correlations were
shown between responses to CQ and MDAQ (r = 0.569;
P < 0.0001), LMF and QN (r = 0.511; P < 0.0001), LMF
and DHA (r = 0.428; P = 0.0001), LMF and MQ (r =
0.413; P = 0.0002), QN and DHA (r = 0.402; P = 0.0003)
and QN and MQ (r = 0.421; P = 0.0001) (Table 3).
Conclusions
This report describes the evaluation of the ex vivo sus-
ceptibility of P. falciparum isolates taken from patients
in Dakar to seven standard anti-malarial drugs. Analysis
of the in vitro susceptibility of P. falciparum isolates has
three important attributes [27]. First, this approach
allows one to assay the response of clinical isolates to
individual drugs that remain intact and unmodified by
important host factors that influence drug efficacy in
vivo. Second, the progressive decline in drug susceptibil-
ity of isolates from the same site may identify incipient
resistance in the parasite population. Finally, strains
with reduced susceptibilities to anti-malarial drugs can
be established in continuous culture, thus providing the
material needed to investigate novel molecular mechan-
isms of resistance. These cultures can also provide
material for tests of susceptibility to other anti-malarial
agents.
This study represents the first use of the 3D7 ratio to
address the requirement of the in vitro module of
WWARN. The use of this 3D7 ratio could allow for the
minimization of bias induced by IC50 variations, which
can be caused by plate batches, atmospheric conditions
and varying methodologies in general. The 3D7 ratio
could allow researchers to compare data and monitor
the spatial and temporal evolution of resistance to anti-
malarial drugs. However, the estimation of the 3D7 ratio
cut-off for in vitro resistance or reduced susceptibility
must be refined by using a large series of 3D7 IC50.
Nevertheless, the results in terms of prevalence of resis-
tance are relatively similar between the two estimations.
Previous ex vivo studies in Dakar and in the Fatick
region (Dielmo and Ndiop, 280 km south-east of Dakar)
were conducted using the same methodology (42-h 3H-
hypoxanthine uptake inhibition method in controlled
atmospheric conditions 5% CO2 and 10% O2)
[24,28-35], while certain conditions varied from that in
the present study (atmospheric generators for capnophi-
lic bacteria Genbag CO2® at 5% CO2 and 15% O2 and
pLDH ELISA). However, the re-evaluation of the cut-off
values for in vitro resistance or reduced susceptibility in
Table 1 Ex vivo susceptibility of 93 Plasmodium falciparum isolates from Dakar to chloroquine (CQ),
monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA), quinine (QN), mefloquine (MQ)
and doxycycline (DOX)
Isolate IC50 Ratio (Isolate IC50 /Mean 3D7 IC50)
Drug No Mean CI95% Min Max Mean CI95% Min Max
CQ 83 34.8 nM 26.9-45.0 4.6 1324 2.1 1.6-2.7 0.26 81.7
MDAQ 83 15.7 nM 12.8-19.4 1.5 82.8 0.8 1.6-2.7 0.07 3.9
LMF 79 21.3 nM 17.1-26.6 1.5 150 0.8 0.6-1.0 0.05 5.8
DHA 88 1.6 nM 1.3-1.8 0.1 9.4 0.9 0.7-1.0 0.05 7.3
QN 82 159 nM 128-197 6.4 1291 1.2 1.0-1.5 0.06 8.6
MQ 88 29.8 nM 24.3-36.5 3.0 170 0.5 0.4-0.7 0.05 3.0
DOX 76 11.6 μM 9.5-14.2 0.5 48.1 1.1 0.9-1.4 0.04 4.7
Mean: geometric mean
CI95%: 95% confidence interval
Table 2 Prevalence of in vitro resistant Plasmodium falciparum isolates from Dakar or with reduced susceptibility to
chloroquine (CQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA), quinine (QN),
mefloquine (MQ) and doxycycline (DOX)
Drug Resistant or reduced susceptible isolate IC50 Resistant or reduced susceptible Ratio (isolate IC50 /3D7 IC50)
Cut-off No % Cut-off No %
CQ 77 nM 18/83 22 5 18/83 22
MDAQ 61 nM 5/83 6 3 5/83 6
LMF 115 nM 3/79 4 5 1/79 1
DHA 12 nM 0/88 0 7 1/88 1
QN 611 nM 9/82 11 5 5/82 6
MQ 30 nM 48/88 55 0.6 44/88 50
DOX 37 μM 6/76 8 3 9/76 12
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these new experimental conditions induced by the use
of the atmospheric generators for capnophilic bacteria
Genbag CO2® allows for the comparison of these data
with previous data assessed by the standard 42-h 3H-
hypoxanthine uptake inhibition method in controlled
incubator conditions (5% CO2 and 10% O2) [25].
Surprisingly, the prevalence of isolates with reduced
susceptibility to MQ reached 50%. This level has
increased since previous studies conducted in Senegal.
In Dielmo and Ndiop, the percent of isolates with
decreased susceptibility was 22% in 1995 [28] and 15%
in 1999 [33,35]. In Dakar, it was 17% in 2001 [36] and
13% in 2002 [24]. Prophylaxis failure with MQ has been
previously described in Senegal [37]. MQ is one of the
three anti-malarial drugs recommended for travellers as
an anti-malarial prophylaxis in Senegal. Clinical trials
are in progress to evaluate the efficacy of MQ for inter-
mittent preventive treatment for infants and during
pregnancy, while MQ is still used for the treatment of
uncomplicated malaria in infants in Dakar. Nevertheless,
MQ has been employed relatively infrequently in Africa
as compared to Asia. The combination artesunate-
mefloquine, which is administered to patients in Asia, is
not yet used in Senegal. However, scientific data are not
available for MQ monotherapy. A positive correlation
was shown between MQ and QN (r = 0.421; r2 = 0.178)
and between the responses to the components of the
ACT used in Dakar, LMF (r = 0.413; r2 = 0.171),
MDAQ (r = 0.412; r2 = 0.170) and DHA (r = 0.402; r2 =
0.161). However, to suggest common mechanisms of
action or resistance for two compounds that could
induce cross-resistance, the coefficient of determination
must be high. A coefficient of determination of 0.161,
0.170, 0.171 and 0.178 means that only 16.1%, 17.0%,
17.1% and 17.8% of the variation in the response to MQ
is explained by the variation in the response to DHA,
MDAQ, LMF and QN, respectively. The IC50 value of
the isolate with the highest DHA IC50 (9.37 nM) was
3.22 nM for MQ. Meanwhile, the IC50 value of the iso-
late with the highest MQ IC50 (170 nM) was 1.63 nM
for DHA. Very few data are available on the in vitro
decreased susceptibility to MQ and its clinical implica-
tions in Africa. It is important to monitor the evolution
of P. falciparum susceptibility to MQ, to archive suspi-
cious isolates and to correlate clinical outcomes with
pharmacokinetic and phenotypic responses and with
molecular markers.
As far back as 1988, in vitro P. falciparum resistance
to CQ was reported in Dakar, and reports of resistance
in other regions of the country followed shortly [38].
From 1991 to 1995, parasitological failures were
observed in 21% of patients in Pikine and in 23% of
patients in another region of Senegal [39]. The in vitro
resistance to CQ increased from 1995 to 1999 in Dielmo
with 32% resistance in 1995 [29] as compared to 49%
resistance in 1996 [30], 44% resistance in 1997 [34] and
55% resistance in 1999 [33]. Certain single nucleotide
polymorphisms (SNPs), such as the P. falciparum chlor-
oquine resistance transporter gene (pfcrt) polymorphism
K76T, are associated with decreased susceptibility to
CQ. Furthermore, this decreased susceptibility to CQ in
Dielmo was confirmed by evaluation of the K76T muta-
tion [40]. In Dielmo, the incidence of clinical malaria for
patients within seven days of CQ treatment increased
from 2.6% in 1995 to 13% in 1999, despite strictly con-
trolled anti-malarial use [40]. A similar increase in in
vitro resistance was seen in Dakar and the suburb of
Pikine with a prevalence of 30% to 31% of strains being
resistant to CQ in 2000 [41,42] increasing to 52% after
2002 [24,43]. The prevalence of the K76T mutation,
which is associated with CQ resistance, was greater than
50% in both 2001 [41,43] and 2002 [24]. In 2009, in
Table 3 Correlation of in vitro responses (Log IC50) of 93 isolates of Plasmodium falciparum from Dakar to chloroquine
(CQ), monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihydroartemisinin (DHA), quinine (QN), mefloquine
(MQ) and doxycycline (DOX)
CQ MDAQ LMF DHA QN MQ DOX
MDAQ r 0.569 1
p-value < 0.0001
LMF r 0.071 0.004 1
p-value 0.5371 0.9732
DHA r 0.044 0.307 0.428 1
p-value 0.7038 0.0065 < 0.0001
QN r 0.205 0.439 0.511 0.402 1
p-value 0.0670 < 0.0001 < 0.0001 0.0003
MQ r 0.267 0.412 0.413 0.357 0.421 1
p-value 0.0180 0.0002 0.0002 0.0008 0.0001
DOX r 0.313 0.025 0.306 0.249 0.318 0.390 1
p-value 0.0105 0.8438 0.0157 0.0347 0.0104 0.0007
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Dakar, only 22% of isolates were found to be resistant ex
vivo to CQ. These data are consistent with the work of
Ndiaye et al., who showed that 23% of parasites were
resistant to CQ in 2007 in Thies (75 km south-east of
Dakar) [44]. This decrease in CQ resistance parallels the
withdrawal of CQ drug treatment and the introduction
of ACT in 2002 in Senegal. However, in 2003, CQ was
still being administered to patients. CQ was found in
the urine samples of two nine-year-old children, with a
prevalence ranging from 14.5% to 47.5% in children
from north Senegal and from 9.0% to 21.4% in children
from south Senegal [45]. In 2006, Senegal reported
10.6% CQ use and 9.7% ACT use [46]. Since 2006, more
than 1.5 million ACT treatments have been adminis-
tered in Senegal [14]. A similar reduction in CQ resis-
tance was reported in Malawi after withdrawal of CQ
treatment [47]. This observation prompted a CQ in vivo
study in Malawi five years later, in which CQ was found
to be 99% effective [48]. The rapid dissemination of CQ
resistance in Dielmo, despite strictly controlled anti-
malarial drug use, argues against the re-introduction of
CQ in places where the resistant allele has dropped to
very low levels following discontinuation of CQ treat-
ment [40].
Encouragingly, only 6% of isolates show in vitro
reduced susceptibility to MDAQ. This rate is stable with
0% resistance in 1996 and 1999 in Dielmo [29,35] and
5% in Mlomp (Casamance, south-western Senegal) in
2004 [49]. The rates remained low even after the intro-
duction of artesunate-amodiaquine in 2002 in Senegal.
A positive correlation was shown between MDAQ and
CQ responses (r = 0.569; r2 = 0.324), which means that
32.4% of the variation in the response to MDAQ is
explained by variation in the response to CQ. A study
in Dakar and Mlomp from 1996 to 1998 showed that
monotherapy with amodiaquine remained effective for
treating uncomplicated malaria in areas where CQ resis-
tance was prevalent [50].
Only one isolate exhibited reduced susceptibility to
DHA. This result is consistent with previous studies
that did not show any parasites resistant to artesunate
[24,33,35]. However, Agnamey et al. reported that 3% -
23% of isolates had IC50 values greater than 15 nM in
Mlomp between 2000 and 2004 [50]. High IC50 values
can also be found for artemisinin with IC50 > 30 nM in
Dakar [44] and artesunate with IC50 > 45 nM [38].
The other ACT first-line treatment for uncomplicated
P. falciparum malaria in Senegal is the combination of
artemether-lumefantrine. Only 1% of the isolates pre-
sented reduced susceptibility to LMF. This prevalence
did not rise in Senegal after the introduction of ACT. In
1996, 6% of isolates from Dielmo were resistant in vitro
to LMF [31].
Six percent of isolates showed reduced susceptibility
to QN, which is in accordance with previous studies in
Dakar [24,36] and Dielmo [28,33,35]. Isolates with high
IC50 to QN were already identified in 1984 [51]. How-
ever, a QN clinical failure was reported in a patient who
spent two months in Dielmo in 2007 [52]. QN is often
associated with DOX in the treatment of severe malaria
in Dakar.
A prevalence of 12% of isolates with in vitro reduced
susceptibility to DOX was observed in Dakar in 2009.
The mean IC50 was similar to those estimated in Dielmo
in 1998 [32,53]. Parasite populations in Senegal were
distributed among three groups with low (4.9 μM), med-
ium (7.7 μM) and high (17.7 μM) IC50 to DOX [53].
The slow activity of DOX in vitro has a delayed effect
upon growth and requires prolonged incubation of para-
sites [32,54]. However, the standard 42-h test is still
used to monitor DOX in vitro susceptibility.
The introduction of ACT in 2002 in Senegal did not
induce a decrease in P. falciparum susceptibility to indi-
vidual drug components, such as DHA, MDAQ and
LMF. However, prevalence of P. falciparum isolates with
reduced drug susceptibility increased for both MQ and
DOX. Clinical failures with QN have been reported in
Senegal. Additionally, isolates with high IC50 values for
artemisinin derivatives have been described for Senegal
and for clinical failures, or at least delayed parasite
clearance times, have been described in Cambodia. For
all of these reasons, an intensive surveillance of the in
vitro P. falciparum susceptibility to anti-malarial drugs
must be conducted in Senegal.
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